ADVENTRX Added to Russell Microcap Index
SAN DIEGO, June 28 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company was added to the Russell Microcap® Index on June 25, 2010, when Russell Investments reconstituted its family of U.S. indexes.
"Our addition to this widely recognized index, available only to companies listed on a national exchange, is consistent with our goal of increasing awareness of the ADVENTRX opportunity among the institutional investment community," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Membership should facilitate our introduction to potential investors, which may prove beneficial as we approach the important milestone of submitting the Exelbine NDA, which is planned for the fourth quarter of this year."
The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. It includes 1,000 of the smallest securities in the small-cap Russell 2000® Index based on a combination of their market cap and current index membership and it includes the next 1,000 securities. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. The indexes are reconstituted annually.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties are fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2009. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
You May Also Like